Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 10/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18151574 | 0.80 | MAP4K4 (0.39) | TRPA1GRM5CYP2D6GSK3BTGFBR1 | |
| SCHEMBL17065178 | 0.76 | GRM5 (0.49) | GRM5CYP2D6GSK3B | |
| SCHEMBL31261370 | 0.76 | CDK8 (0.56) | TRPA1KDM1ANR3C1CCNCCDK8 | |
| SCHEMBL18151247 | 0.76 | TRPA1 (0.47) | TRPA1GRM5GSK3B | |
| SCHEMBL31261355 | 0.73 | KDM1A (0.46) | TRPA1KDM1A | |
| SCHEMBL18151805 | 0.72 | GRM5 (0.40) | KDM1AGRM5CYP2D6GSK3BTGFBR1 | |
| SCHEMBL18150868 | 0.72 | GRM5 (0.41) | TRPA1GRM5GSK3B | |
| SCHEMBL18151684 | 0.72 | GRM5 (0.40) | TRPA1GRM5CYP2D6GSK3BTGFBR1 | |
| SCHEMBL16797340 | 0.71 | GRM5 (0.42) | GRM5CYP2D6GSK3BTGFBR1 | |
| SCHEMBL18151458 | 0.71 | GRM5 (0.39) | TRPA1GRM5CYP2D6GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-10131664-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9944636-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | TRPA1 4680/4885KDM1A 2/4885NR3C1 3023/4885 |
| US-10131664-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | TRPA1 4680/4885KDM1A 2/4885NR3C1 3023/4885 |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | TRPA1 4680/4885KDM1A 2/4885NR3C1 3023/4885 |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | TRPA1 4680/4885KDM1A 2/4885NR3C1 3023/4885 |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | TRPA1 4680/4885KDM1A 2/4885NR3C1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.